The FDA has approved Eli Lilly's Jaypirca as a first-line therapy for chronic lymphocytic leukemia (CLL), according to STAT News. The approval moves Jaypirca, already known in CLL treatment discussions, into the earlier-line setting. Details of the decision are behind the STAT+ paywall, with further coverage available to subscribers.
Why it matters: First-line CLL approval expands the eligible patient population for Lilly's Jaypirca.
FDA approved Eli Lilly's pirtobrutinib (Jaypirca) on October 2, 2026 for adults with previously untreated CLL or SLL without 17p deletion. In the BRUIN CLL-313 trial of 282 patients randomized to pirtobrutinib or bendamustine plus rituximab, median PFS was not estimable with pirtobrutinib versus 33.5 months in the control arm (hazard ratio 0.20, p<0.0001) at a median follow-up of 28 months. The recommended dose is 200 mg orally once daily until progression or unacceptable toxicity.
Why it matters: FDA approval of pirtobrutinib moves the BTK inhibitor into first-line CLL/SLL treatment based on a 0.20 hazard ratio.
The FDA approved Eli Lilly's combination drug treatment for patients with an advanced form of breast cancer, reported Sept. 21, 2026. The decision gives Lilly a new option in the advanced breast cancer setting. Full details of the approval are available to STAT+ subscribers.
Why it matters: FDA approval of a Lilly combination therapy for advanced breast cancer directly affects oncology treatment options.
Eli Lilly has won FDA approval for Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes. The decision adds a cardiovascular risk reduction use to the drug as Lilly competes with Novo Nordisk in diabetes and obesity. Lilly secured the approval on Friday.
Why it matters: FDA approval extends Mounjaro's use to cardiovascular risk reduction in type 2 diabetes, intensifying competition with Novo Nordisk.
NICE has recommended Eli Lilly's once-weekly insulin Onswik for NHS coverage in Type 2 diabetes, based on the QWINT-1, QWINT-3 and QWINT-4 trials, which showed non-inferior A1C reduction and similar safety versus daily insulins degludec and glargine. Hundreds of thousands of UK patients could cut annual injections by 85% if approved. Lilly awaits MHRA marketing authorization, with an FDA decision possible by year-end and a CHMP opinion already secured pending European Commission sign-off.